Given that ACE2 is a major molecule mediating infection, Monteil et al. (2020) attempted to inhibit viral infection by blocking the ACE2 receptor, and they used human recombinant soluble ACE2 (hrsACE2, human recombinant soluble ACE2) to treat virus-infected vascular and kidney organoids. Here, ACE2 is linked to viral infectious disease.